Xu Wenjing, Barrientos Tomasa, Mao Lan, Rockman Howard A, Sauve Anthony A, Andrews Nancy C
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Duke University, Durham, NC 27705, USA.
Department of Medicine, Duke University School of Medicine, Duke University, Durham, NC 27705, USA.
Cell Rep. 2015 Oct 20;13(3):533-545. doi: 10.1016/j.celrep.2015.09.023. Epub 2015 Oct 8.
Both iron overload and iron deficiency have been associated with cardiomyopathy and heart failure, but cardiac iron utilization is incompletely understood. We hypothesized that the transferrin receptor (Tfr1) might play a role in cardiac iron uptake and used gene targeting to examine the role of Tfr1 in vivo. Surprisingly, we found that decreased iron, due to inactivation of Tfr1, was associated with severe cardiac consequences. Mice lacking Tfr1 in the heart died in the second week of life and had cardiomegaly, poor cardiac function, failure of mitochondrial respiration, and ineffective mitophagy. The phenotype could only be rescued by aggressive iron therapy, but it was ameliorated by administration of nicotinamide riboside, an NAD precursor. Our findings underscore the importance of both Tfr1 and iron in the heart, and may inform therapy for patients with heart failure.
铁过载和铁缺乏均与心肌病和心力衰竭有关,但心脏铁利用情况尚未完全明确。我们推测转铁蛋白受体(Tfr1)可能在心脏铁摄取中发挥作用,并利用基因靶向技术在体内研究Tfr1的作用。令人惊讶的是,我们发现由于Tfr1失活导致的铁减少与严重的心脏后果相关。心脏中缺乏Tfr1的小鼠在出生后第二周死亡,出现心脏肥大、心脏功能不佳、线粒体呼吸衰竭和无效的线粒体自噬。该表型只能通过积极的铁疗法挽救,但烟酰胺核糖苷(一种NAD前体)的给药可使其改善。我们的研究结果强调了Tfr1和铁在心脏中的重要性,并可能为心力衰竭患者的治疗提供参考。